HK1250941A1 - 針對白細胞介素36受體(il-36r)的抗體 - Google Patents

針對白細胞介素36受體(il-36r)的抗體

Info

Publication number
HK1250941A1
HK1250941A1 HK18110434.3A HK18110434A HK1250941A1 HK 1250941 A1 HK1250941 A1 HK 1250941A1 HK 18110434 A HK18110434 A HK 18110434A HK 1250941 A1 HK1250941 A1 HK 1250941A1
Authority
HK
Hong Kong
Prior art keywords
receptor
directed against
antibodies directed
against interleukin
interleukin
Prior art date
Application number
HK18110434.3A
Other languages
English (en)
Inventor
Peter Bowers
Andrew John Mcknight
David J King
Marco Londei
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of HK1250941A1 publication Critical patent/HK1250941A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK18110434.3A 2015-04-15 2018-08-14 針對白細胞介素36受體(il-36r)的抗體 HK1250941A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562147824P 2015-04-15 2015-04-15
PCT/US2016/027676 WO2016168542A1 (en) 2015-04-15 2016-04-15 Antibodies directed against interleukin 36 receptor (il-36r)

Publications (1)

Publication Number Publication Date
HK1250941A1 true HK1250941A1 (zh) 2019-01-18

Family

ID=57126337

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18110434.3A HK1250941A1 (zh) 2015-04-15 2018-08-14 針對白細胞介素36受體(il-36r)的抗體
HK18111338.8A HK1252009A1 (zh) 2015-04-15 2018-09-04 針對白細胞介素36受體(il-36r)的抗體

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18111338.8A HK1252009A1 (zh) 2015-04-15 2018-09-04 針對白細胞介素36受體(il-36r)的抗體

Country Status (17)

Country Link
US (3) US10526410B2 (zh)
EP (2) EP4176900A1 (zh)
JP (3) JP6913026B2 (zh)
KR (1) KR102666920B1 (zh)
CN (2) CN115925932A (zh)
AU (1) AU2016248208B2 (zh)
BR (1) BR112017022086A2 (zh)
CA (1) CA2982555A1 (zh)
DK (1) DK3283110T3 (zh)
ES (1) ES2914243T3 (zh)
HK (2) HK1250941A1 (zh)
MX (2) MX2017013080A (zh)
NZ (1) NZ736535A (zh)
PL (1) PL3283110T3 (zh)
RU (1) RU2745898C2 (zh)
SG (1) SG11201708061TA (zh)
WO (1) WO2016168542A1 (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107007833B (zh) 2011-11-16 2020-12-11 勃林格殷格翰国际有限公司 抗il-36r抗体
EP4176900A1 (en) * 2015-04-15 2023-05-10 AnaptysBio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
WO2018183173A1 (en) * 2017-03-27 2018-10-04 Boehringer Ingelheim International Gmbh Anti il-36r antibodies combination therapy
EP3400962A1 (en) 2017-05-09 2018-11-14 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Inhibitors of il-38 for use in treating and/or preventing cancer in a subject
EP3765515A2 (en) * 2018-03-14 2021-01-20 Boehringer Ingelheim International GmbH Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
KR20200131871A (ko) * 2018-03-14 2020-11-24 베링거 인겔하임 인터내셔날 게엠베하 전신성 농포 건선의 치료를 위한 항-il-36r 항체의 용도
EP3823989A2 (en) * 2018-07-16 2021-05-26 Regeneron Pharmaceuticals, Inc. Anti-il36r antibodies
SG11202011284RA (en) * 2018-07-16 2020-12-30 Regeneron Pharma Non-human animal models of ditra disease and uses thereof
CN110818796B (zh) * 2018-08-09 2022-11-08 东莞市朋志生物科技有限公司 一种抗人ca153蛋白的重组抗体
AR123405A1 (es) 2018-12-21 2022-11-30 23Andme Inc Anticuerpos anti-il-36 y métodos de uso de estos
KR20210119407A (ko) * 2018-12-27 2021-10-05 베링거 인겔하임 인터내셔날 게엠베하 수장 족저 농포증 치료용 항-il-36r 항체
MX2021010783A (es) * 2019-03-08 2021-09-30 Boehringer Ingelheim Int Formulaciones de anticuerpo anti-il-36r.
US11142586B2 (en) 2019-08-07 2021-10-12 Aqualung Therapeutics Anti-human nicotinamide phosphoribosyltransferase (NAMPT) antibodies
WO2021112196A1 (ja) * 2019-12-05 2021-06-10 学校法人東京薬科大学 筋組織の減少を抑制するための組成物
AR120913A1 (es) * 2019-12-27 2022-03-30 Teijin Pharma Ltd Anticuerpo que inhibe específicamente la señalización de il-36r
JP2023534955A (ja) * 2020-07-17 2023-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 好中球性皮膚症の処置のための抗ｉｌ－３６ｒ抗体
IL299648A (en) 2020-07-30 2023-03-01 Anaptysbio Inc Anti-interleukin 36 receptor therapy for psoriasis
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
US20240084021A1 (en) 2021-01-08 2024-03-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
US20220290239A1 (en) 2021-03-12 2022-09-15 Boehringer Ingelheim International Gmbh Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
JP2024518536A (ja) * 2021-05-12 2024-05-01 アナプティスバイオ インコーポレイティッド 抗体組成物
EP4370550A1 (en) 2021-07-12 2024-05-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
TW202323293A (zh) * 2021-10-29 2023-06-16 新加坡商創響私人有限公司 新型抗ｉｌ－３６ｒ抗體
CN115724975A (zh) * 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
DE69128037T2 (de) 1990-11-13 1998-05-07 Immunex Corp., Seattle, Wash. Bifunktionelle wählbare fusionsgene
CA2163427A1 (en) 1993-05-21 1994-12-08 Stephen D. Lupton Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
WO2001057219A2 (en) 2000-02-02 2001-08-09 Schering Corporation Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
CA2662549C (en) 2006-09-08 2014-10-28 Amgen Inc. Il-1 family variants
WO2008103474A1 (en) 2007-02-20 2008-08-28 Anaptysbio, Inc. Methods of generating libraries and uses thereof
WO2010025369A2 (en) 2008-08-28 2010-03-04 Wyeth Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
CN107007833B (zh) * 2011-11-16 2020-12-11 勃林格殷格翰国际有限公司 抗il-36r抗体
PL2797951T3 (pl) * 2011-12-28 2018-07-31 Immunoqure Ag Sposób izolacji ludzkich przeciwciał
US9409977B2 (en) * 2013-03-12 2016-08-09 Decimmune Therapeutics, Inc. Humanized, anti-N2 antibodies
EP4176900A1 (en) * 2015-04-15 2023-05-10 AnaptysBio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
WO2018183173A1 (en) 2017-03-27 2018-10-04 Boehringer Ingelheim International Gmbh Anti il-36r antibodies combination therapy
EP3765515A2 (en) 2018-03-14 2021-01-20 Boehringer Ingelheim International GmbH Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
KR20200131871A (ko) 2018-03-14 2020-11-24 베링거 인겔하임 인터내셔날 게엠베하 전신성 농포 건선의 치료를 위한 항-il-36r 항체의 용도
EP3823989A2 (en) 2018-07-16 2021-05-26 Regeneron Pharmaceuticals, Inc. Anti-il36r antibodies
AR123405A1 (es) 2018-12-21 2022-11-30 23Andme Inc Anticuerpos anti-il-36 y métodos de uso de estos
KR20210119407A (ko) 2018-12-27 2021-10-05 베링거 인겔하임 인터내셔날 게엠베하 수장 족저 농포증 치료용 항-il-36r 항체
MX2021010783A (es) 2019-03-08 2021-09-30 Boehringer Ingelheim Int Formulaciones de anticuerpo anti-il-36r.
CN113316587B (zh) 2019-05-20 2024-03-26 南通壹宸生物医药科技有限公司 一种双特异性分子及其制备与用途

Also Published As

Publication number Publication date
CA2982555A1 (en) 2016-10-20
ES2914243T3 (es) 2022-06-08
JP2023040236A (ja) 2023-03-22
AU2016248208B2 (en) 2022-03-24
JP2018512157A (ja) 2018-05-17
PL3283110T3 (pl) 2022-06-27
EP3283110A4 (en) 2019-02-27
CN115925932A (zh) 2023-04-07
US11130814B2 (en) 2021-09-28
US20180094065A1 (en) 2018-04-05
JP6913026B2 (ja) 2021-08-04
KR102666920B1 (ko) 2024-05-20
MX2017013080A (es) 2018-02-09
EP3283110B1 (en) 2022-04-20
CN107847590A (zh) 2018-03-27
US20200087408A1 (en) 2020-03-19
RU2017139481A (ru) 2019-05-15
WO2016168542A1 (en) 2016-10-20
RU2745898C2 (ru) 2021-04-02
AU2016248208A1 (en) 2017-11-09
KR20180002687A (ko) 2018-01-08
US10526410B2 (en) 2020-01-07
SG11201708061TA (en) 2017-10-30
JP2021118710A (ja) 2021-08-12
CN107847590B (zh) 2022-07-26
EP4176900A1 (en) 2023-05-10
HK1252009A1 (zh) 2019-05-10
US20210388095A1 (en) 2021-12-16
RU2017139481A3 (zh) 2019-09-19
BR112017022086A2 (pt) 2018-07-03
EP3283110A1 (en) 2018-02-21
DK3283110T3 (da) 2022-05-23
JP7212098B2 (ja) 2023-01-24
MX2023001791A (es) 2023-03-10
NZ736535A (en) 2024-08-30

Similar Documents

Publication Publication Date Title
HK1252009A1 (zh) 針對白細胞介素36受體(il-36r)的抗體
IL268517A (en) Anti-tigit antibodies
IL272227A (en) ANTI-TIGIT antibodies
ZA201905966B (en) Anti-lag3 antibodies
PL3625259T3 (pl) Przeciwciała anty-sirpalfa
HK1249114A1 (zh) 針對bcma的單克隆抗體
GB201709808D0 (en) Antibodies
HK1253695A1 (zh) T細胞受體特異性抗體
SG10201914130VA (en) GARP-TGF-β ANTIBODIES
ZA202002141B (en) Anti-transthyretin antibodies
IL275079A (en) DARIC interleukin receptors
GB201720970D0 (en) Antibodies
ZA202103456B (en) Anti-alpha-synuclein antibodies
IL271067A (en) Anti-trkb antibodies
GB201711785D0 (en) Antibodies
GB201717006D0 (en) Anti-OPG antibodies
GB201709818D0 (en) Antibodies
GB201703071D0 (en) Antibodies
GB201701416D0 (en) Anti-OPG antibodies